Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025. Merck (NYSE: MRK), known as MSD outside of the United States and Canada ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse ...

Merck (NYSE:MRK) recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ...

Merck & Co. said the U.S. Food and Drug Administration will review its application seeking approval of its proposed doravirine/islatravir regimen in certain adults with HIV-1 infection. Merck on ...

Merck, known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International ...

Merck, known as MSD outside of the United States and Canada, announced that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be ...